The Team

Professor Sabine Bahn
Professor Sabine Bahn
Professor Sabine Bahn - Chief Medical Officer
Co-founder of Psyomics Ltd
Sabine has dedicated more than 25 years to researching the molecular basis of mental illness, co-authoring more than 200 research papers on disorders including bipolar disorder and major depressive disorder. Her research group has contributed to launching the world’s first commercially available diagnostic aid for schizophrenia in collaboration with the NASDAQ-listed diagnostics company Myriad Genetics Inc.
As co-founder of Psyomics Ltd, and head of the Cambridge Centre for Neuropsychiatric Research, Sabine is leading a team of scientists working on developing blood-based tests for bipolar disorder and major depression, as well incorporating evidence-based mental health research into the development of our digital tools. As a practicing psychiatrist at the Cambridge and Peterborough NHS trust, Sabine has direct experience of the clinical need for new digital and biological tools for tackling some of the fundamental challenges in mental health.
Daniel Cowell
Daniel Cowell
Daniel Cowell - CEO
Co-founder of Psyomics Ltd
Daniel has spent the past 18 years leading the commercial, and scientific direction of various UK based biotechnology companies, in fields ranging from oncology to translational genomics research. He has previously co-founded the companies Pharmorphix, a drug discovery company which was subsequently acquired by Sigma Aldrich, and Hypoxium, a company providing custom cell biology research services for the development of novel oncology therapeutics which was then acquired by Horizon Discovery. As co-founder of Psyomics Ltd, Daniel is leading the commercial, strategic, clinical and scientific direction of the development of the company’s new digital tools, offering diagnosis and self-help solutions for mental health concerns.
Giles Barton-Owen
Giles Barton-Owen
Giles Barton-Owen
Chief Technology Officer
Giles has over 6 years’ professional experience in technology and software development, independently consulting on various technology and research projects for a range of organisations and initiatives before joining Psyomics in 2016. A computer science graduate from the University of Cambridge, Giles has a particular interest in data science, cross-disciplinary technologies and difficult-to-formalise problems. He has worked on many notable projects including a study conducted by the United Nations using big data to understand the effectiveness of various UN Women programs. As Chief Technology Officer, Giles leads and oversees all aspects of technology in the company, from research and development to the finalised products. His involvement ensures that all products are built to the highest standards of reliability and security while allowing the company to deliver innovation swiftly and efficiently.
Jade Kerri-Dibb
Jade Kerri-Dibb
Jade Kerri-Dibb
Chief Operations Officer
Jade has over 15 years of international experience in managing core business operations for successful biotech companies. Jade has held Director and Head of Operations roles at successful businesses such as Horizon Discovery, managing sites in the UK and US, and Fluidic Analytics, leading them from start-up to international enterprises. Jade joined Psyomics in September 2019 as Chief Operations Officer, overseeing core busines operations working alongside the CEO and senior management team. Jade has a great understanding of how to build and manage scalable, operationally excellent businesses, through implementing effective business processes building high performing teams to support business growth. She is currently completing her MBA in Business Management and Innovation.
Lynn Farrag
Lynn Farrag
Lynn Farrag
Head of Regulatory
Lynn has spent 37 years working in a clinical environment, with experience as a project manager, head of clinical operations at a range of pharmaceutical and medical device manufacturing companies. Lynn has considerable experience in running clinical trials, as well as ensuring that company products met regulatory and international standards to be registered for use in EU. She is also a qualified ISO 13485 auditor. Within Psyomics, Lynn is responsible for implementing and adherence to regulatory standards relating to medical devices in the development of the company’s digital and biological tools. She also conducts clinical investigations in accordance with international standards and ICH-GCP.
Sharmelee Thiahulan
Sharmelee Thiahulan
Sharmelee Thiahulan
Head of Quality Systems
Sharmelee has two decades experience as a quality management consultant and regulatory professional in the pharmaceutical and medical device industries with a focus on diagnostic technologies. Sharmelee has experience in implementing and supporting quality management systems including ISO 9001, ISO 13485, CMDR SOR/98-282 and 21 CFR 820, as well as being a BSI qualified Lead ISO 13485 auditor, and a qualified PRINCE2 practitioner.
As part of the Psyomics team, Sharmelee’s experience will be integral to ensuring that all Psyomics products meet the latest medical device requirements according to the International Organisation for Standardization.
Emily Bell
Emily Bell
Emily Bell
Product Director
Emily has 9 years of experience working as a freelance producer, managing projects from the concept development stage through to finalised products, for a range of leading brands. Emily joined Psyomics initially in 2016 as a freelance producer and since joined the team full-time. At Psyomics, Emily is the Product Director, where she is responsible for product strategy,  the delivery of the software platform including production partner selection, contracts, briefing, managing the Psyomics team workflow and ensuring clear communication between the research, commercial and regulatory teams.
Kalhari Palihakkara
Kalhari Palihakkara
Kalhari Palihakkara
Financial Controller
Kalhari has worked in the UK finance sector for more than 15 years, with five years’ experience as a senior accountant in an audit practice and seven years as a finance manager in the biotechnology sector. She has been an associate member of the Chartered Institute of Management Accountants since 2008. At Psyomics, Kalhari’s experience as a financial controller is invaluable in producing timely, accurate financial information for the board, as well as preparing budgets and business plan forecasts to assist with year-end processes and statutory accounts preparation.

Service User Advisory Group

Service User Advisory Group
Service User Advisory Group
Service User Advisory Group
All aspects of our research and development are conducted in collaboration with a team of 10 individuals who have had first-hand experiences of existing mental health challenges within the healthcare system either as patients or carers. At Psyomics, we believe that the needs of patients and their families come first, and receiving the feedback and perspectives of this team - including concerns, suggestions for improvement, and recommendations - is invaluable to ensure that the tools we are developing are best suited to meet the needs of those they are intended to help.

Board and Advisors

Kevin McDonnell
Kevin McDonnell
Kevin McDonnell
Chairman
Kevin has over 20 years leadership experience running global operations in varied business environments with a focus on the healthcare technology sector. He has an in-depth knowledge and understanding of UK and international healthcare sectors and currently serves as Chairman of Medic Creations Ltd and Jiva.ai Ltd and is the founder and CEO of Datalla Group Ltd.
Kevin is an advisor to several leading companies and is also an accomplished speaker on future trends, growth, scaling, strategy, corporate governance, leadership and organisational development. Previous experiences include Business Director at Capita, Managing Director of EMIS Group Plc’s EMIS Care and EMIS Health Specialist divisions and CEO of Digital Healthcare Ltd.
Kevin’s extensive industry knowledge and direction as Chairman of the board is integral for Psyomics’ commercial growth and ensuring the company achieves its financial, operational and organisational goals.
Dr Neil Hunt
Dr Neil Hunt
Dr Neil Hunt
Advisor
Neil has been a consultant psychiatrist based in Cambridge for more than 20 years, and a member of the Royal College of Psychiatrists since 1987. He has co-authored numerous research papers in leading medical and psychiatric journals including the Lancet, over the past three decades, and is an author of two books including ‘Bipolar Disorder - Your Questions Answered.’ As a member of the Psyomics Advisory Board, Neil’s many years of clinical experience in treating patients with mental illnesses are invaluable in ensuring that our technologies address the needs of clinicians to aid them with early diagnosis, as well as ensuring that they provide patients with appropriate feedback and recommendations for self-help.
Dr Anne Dobree
Dr Anne Dobree
Dr Anne Dobree
Non-executive Director
Anne has 20 years of experience in helping university researchers commercialise their technology, and launch successful independent businesses based on their findings. Anne has been part of the University of Cambridge technology transfer team since 2001, holding a number of roles with Cambridge Enterprise including Head of Technology Transfer, and Head of Seed Funds. During her time with Cambridge Enterprise, Anne has supported numerous early stage companies, serving on the boards of Pneumacare, Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies and others. She is also a founding member of Praxis, the UK Technology Transfer Training Programme. As Non-Executive Director on Psyomics’ Board, Anne brings considerable experience in turning research into successful commercial technologies, and delivering value to stakeholders.
David Blair
David Blair
David Blair
Chief Financial Officer
David has spent the past 25 years working with more than 50 high growth companies, helping them raise and successfully deploy in excess of £250m from public and private funds, and execute a variety of successful exits including merger, trade sale and IPO. David has also worked closely with financial providers, spending four years as Company Secretary of Prelude Trust plc, a main market listed Investment Trust, and since 2008 he has been CFO of Wyvern Fund, which invests in early stage technology companies. As Chief Financial Officer for Psyomics, David has proven experience in helping businesses build shareholder value, so entrepreneurs and investors alike can achieve their objectives. In addition, much of his previous work has seen him specialise in advising SMEs in the life science and technology arenas.
Barnaby Perks
Barnaby Perks
Barnaby Perks
Non-executive Director
Barnaby has been involved in building and growing digital health businesses for the past decade, currently serving as the CEO of Oxford VR, a University of Oxford spinout which uses virtual reality technology to deliver psychological interventions to patients. Barnaby also serves as the director of Tentsmuir Ltd, a company which provides practical support for digital health businesses, raising the funding required to turn innovative ideas into commercial success. As a non-executive director of Psyomics, Barnaby supports the company with its commercial strategy. His experience as founding CEO of Ieso Digital Health is particularly relevant to Psyomics future plans. Over the course of seven years, Barnaby built Ieso to become UK’s leading provider of live online cognitive behavioural therapy, obtaining multiple contracts with the NHS and Medicaid patients in the US, to deliver evidence-based mental health therapy services.
Martin Glen
Martin Glen
Martin Glen
Non-executive Director
Martin currently serves as an investment director for Parkwalk Advisors, and sits on the board of various portfolio companies, managing investments in UK university spinouts on behalf of EIS clients. Prior to that, he accumulated 25 years experience as a hedge fund manager and equities analyst, focusing on IPOs and follow-on deals. He has also been an Extel-rated analyst and an investment banker at various institutions including Lazard and Jeffries. As a non-executive director, Martin brings extensive experience to the Psyomics Board in terms of commercial and financial strategy.
Cambridge Innovation Centre, 320 Cambridge Science Park Milton Road, Cambridge, CB4 0WG
PsyOmics Ltd is registered in England and Wales (Registered number: 09470381)
Registered Office: Beech House, 4a Newmarket Road, Cambridge, CB5 8DT
VAT Registration No. 233 2946 14